Representative before the EPO

Technology company logo thumb
no operation time available
3 offices
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
4 offices
Technology Company

We have observed 10 EP applications Raymond Stevenson Gairns has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after September 19, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12832680

METHODS AND COMPOSITIONS FOR TREATING, REVERSING, INHIBITING OR PREVENTING RESISTANCE TO ANTIPLATELET THERAPY

IPC classification:
A61K 31/20
Agent:
WP Thompson
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Agent:
Sarah Elizabeth Roques, J A Kemp
Status:
GRANT OF PATENT INTENDED
EP12795842

COMBINATION TREATMENT OF CANCER

IPC classification:
A61K 31/519, A61P 35/00, A61P 13/08
Applicant:
AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
GRANT OF PATENT INTENDED
EP13715426

HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS

IPC classification:
A61K 31/439, C07D 471/08, A61P 31/04
Applicant:
AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Agent:
Anthony James Proctor, Potter Clarkson LLP
Status:
The patent has been granted
EP13198224

Certain triazolopyrazines, compositions thereof and methods of use therefor

IPC classification:
A61K 31/4985, A61K 31/437, C07D 519/00, C07D 487/04, C07D 471/04, A61P 35/00
Agent:
Raymond Stevenson Gairns, AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13718618

CRYSTALLINE FORMS OF (S) -4-AMINO-N- (1- (4 - CHLOROPHENYL) - 3 - HYDROXYPROPYL) -1- (7H - PYRROLO [2, 3-D]PYRIMIDI N-4-YL) PIPERIDINE-4-CARBOXAMIDE

IPC classification:
A61K 31/519, C07D 487/04, A61P 35/00
Applicant:
AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
The patent has been granted
EP13821906

PHARMACEUTICAL FORMULATION OF N- [5- [2-(3,5-DIMETHOXYPHENYL) ETHYL]-2H-PYRAZOL-3-YL]-4-[(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE

IPC classification:
A61K 31/496, A61K 9/46, A61K 9/20, A61K 9/16
Applicant:
AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
GRANT OF PATENT INTENDED
EP15170608

CERTAIN TRIAZOLOPYRIDINES, COMPOSITIONS THEREOF AND THEIR USE IN THE TREATMENT OF CANCER.

IPC classification:
C07D 519/00, A61P 35/00, A61K 31/437, A61K 31/4985, C07D 471/04, C07D 487/04
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
EXAMINATION IN PROGRESS
EP11805575

PURINE DERIVATIVES

IPC classification:
A61K 31/522, C07D 473/18
Applicant:
Sumitomo Dainippon Pharma Co., Ltd.
Applicant:
AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Agent:
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Status:
PATENT GRANTED
EP11805574

IMIDAZO[4,5-C]QUINOLIN-1-YL DERIVATIVE USEFUL IN THERAPY

IPC classification:
A61P 1/16, A61P 31/04, A61P 31/18, A61P 31/12, A61P 17/12, A61P 17/04, A61P 37/08, A61P 17/06, A61P 11/06, A61K 31/4745, A61K 31/4188, C07D 471/04
Applicant:
Sumitomo Dainippon Pharma Co., Ltd.
Applicant:
AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Agent:
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP15726257

METHOD FOR SUPPRESSING GLUCAGON SECRETION OF AN SGLT2 INHIBITOR

IPC classification:
A61K 31/155, A61K 38/28, A61P 3/10, A61K 31/7042, A61K 31/70, A61K 31/522, A61K 31/4985, A61K 31/403, A61K 31/40
Applicant:
AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca AB
Agent:
Raymond Stevenson Gairns, AstraZeneca PLC
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature